Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNE PHARMACEUTICALS, INC.

(IMNPQ)
 SummaryQuotesChartsNewsCompany 
Quotes 5-day view   Delayed Quote. Delayed Otc Markets
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
0.001(c) 0.002(c) 0(c) 0.001(c) 0.001 Last
77 055 385 000 1 280 9 393 Volume
0.00% +100.00% -100.00% 0.00% Change
More quotes
Company
Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The... 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about IMMUNE PHARMACEUTICALS, INC.
04/13IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in..
AQ
04/12IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form..
AQ
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2020Motion For Case Conversion Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals, Inc. cancelled the transaction announced on October 9, 2018
CI
2019Motion for Case Conversion or Dismissal Filed for Immune Pharmaceuticals, Inc.
CI
2019Bidding Procedure Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Case Conversion Filed by Immune Pharmaceuticals, Inc.
CI
2019First Motion for Exclusivity Period Extension Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals Announces Leadership Transition
CI
2019Motion for Joint Administration Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Joint Administration Filed by Immune Pharmaceuticals, Inc.
CI
More news
News in other languages on IMMUNE PHARMACEUTICALS, INC.

- No features available -

More news
Chart IMMUNE PHARMACEUTICALS, INC.
Duration : Period :
Immune Pharmaceuticals, Inc. Technical Analysis Chart | IMNPQ | US45254C2008 | MarketScreener
Managers and Directors
Adeel Ahmed-Daudpota President & Chief Executive Officer
Devin J. Shaw Chief Financial Officer
John Zhang Vice President-Research & Development
John A. Neczesny Independent Director
Jeffrey Paley Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNE PHARMACEUTICALS, INC.-90.00%0
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979